Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Calcium channel blocker and antihistamine derived from piperazine with sedative effect. Used for the prophylaxis of migraines and vertigo. Oral administration in one daily dose, preferably at night due to the sedation it causes.
At the date of the last update, we found no published data on its excretion in breast milk.
Its very high binding to plasma proteins, very high volume of distribution and moderately high molecular weight make it difficult to excrete in breast milk, but its very long half-life (18 days) may facilitate excretion.
It increases prolactin levels (Formisano 1991, Cortelli 1988 and 1985, Bonuccelli 1988, Maestri 1987) and induces parkinsonism. (Teive 2004)
Until more data on this drug in relation to breastfeeding is known, safer alternatives are preferable - Propranolol, Metoprolol, Sertraline, Escitalopram, Amitrptyline or Valproate in migraine prophylaxis (Pringsheim 2012, Davanzo 2014) and Nimodipine, Betahistine or Ginkgo biloba in the prophylaxis of vertigo - especially in the neonatal period and in case of prematurity.
If this medicine is taken during breastfeeding, sleepiness and adequate feeding of the infant should be monitored and bed-sharing with the baby (co-sleeping) is not recommended. (ABM 2020 and 2008, UNICEF 2018, 2017, 2017, 2014 and 2013, Landa 2012, UNICEF 2006)